Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 497

Document Document Title
WO/2018/107112A1
Embodiments are directed to compounds of the formulae (I), (Ia), (Ib), (II), (IIa) (III), (IV), (V), and (VI); methods for treating cancer with one or more compounds of the formulae (I), (Ia), (Ib), (II), (IIa); (III), (IV), (V), and (VI...  
WO/2018/057389A1
A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent compositi...  
WO/2018/057387A1
Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H co...  
WO/2018/057388A1
Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrat...  
WO/2018/057386A1
Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent...  
WO/2018/051255A1
The present invention relates to cyclic substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an...  
WO/2018/051254A1
The present invention relates to cyclic substituted-1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signalling pathway and/or for treatment of disorders by inhibiting an immunosuppress...  
WO/2018/047143A1
The present invention relates to VISTA signaling pathway inhibitory compounds of formula (I) which are useful as immune modulators for the treatment of various disease conditions including various types of cancer. The invention also enco...  
WO/2017/175177A1
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for maki...  
WO/2017/044571A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...  
WO/2017/036404A1
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine ...  
WO/2017/024229A8
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...  
WO/2017/024229A1
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...  
WO/2017/001655A1
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...  
WO/2016/197398A1
Disclosed are a sulfonic acid inner salt compound of amidine and a preparation method therefor. The product of a sulfonic acid inner salt of amidine is obtained and synthesized by adopting an o-aminobenzenesulfonyl chloride compound and ...  
WO/2016/116525A1
The invention relates to organic molecules, in particular for use in optoelectronic components, such as OLEDs. According to the invention, the organic molecule has a structure of formula 1. In formula 1, n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9...  
WO/2016/098054A9
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infectio...  
WO/2016/098054A1
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infectio...  
WO/2016/055802A1
The present invention relates to tetrazole compounds which are of use in the field of agriculture, as fungicides.  
WO/2016/030790A1
Oxime sulfonate compounds of the formula (I), wherein R 1 is O(CO)R 4, COOR 5 or CONR 6R 7; n is 1 or 2; R 2 for example is C 1-C 8alkyl, C 3-C 6cycloalkyl or benzyl; R 3 is for example C 1-C 8alkyl, C 3-C 6cycloalkyl, C 1-C 8haloalkyl, ...  
WO/2015/143652A1
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/143652A8
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/123365A1
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leig...  
WO/2015/110262A1
The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention f...  
WO/2014/173928A1
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopur...  
WO/2014/079935A9
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, G1, n, A1, A2, A3, and A4 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to insectici...  
WO/2014/079935A1
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, G1, n, A1, A2, A3, and A4 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to insectici...  
WO/2014/049107A1
The present invention concerns compounds of general formula (I): (I) in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or ...  
WO/2014/003124A1
The compound represented by formula (1) or a salt thereof has a collagen production-inhibiting effect, and is thus useful for use in the prevention, treatment, or the like of diseases associated with overproduction of collagen such as pu...  
WO/2013/190355A1
New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.  
WO/2013/182651A1
In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammoni...  
WO/2013/139697A1
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...  
WO/2013/119564A1
It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequ...  
WO/2013/096152A1
In one embodiment, the invention is to a process for purifying a by-product stream. The process comprises the step of providing a by-product stream comprising an ammonium salt, dimerized amide, and optionally water. The process further c...  
WO/2013/033245A1
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...  
WO/2013/006485A1
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...  
WO/2012/146572A1
To provide pesticidal allylAryl heterocycle derivatives that are useful as a pesticidal compound. Pesticidal allylAryl heterocycle derivatives that are expressed by the Formula (I) and pesticides and an agent for controlling animal paras...  
WO/2012/125926A3
The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates...  
WO/2012/120055A1
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.  
WO/2012/120050A1
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.  
WO/2012/120058A1
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.  
WO/2012/120051A1
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.  
WO/2012/120057A1
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.  
WO/2012/120053A1
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.  
WO/2012/120056A1
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.  
WO/2012/120054A1
The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.  
WO/2012/120052A1
The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.  
WO/2012/101245A1
The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QAaBbCc where a is 0, 1, 2, 3, 4 or 6, b ...  
WO/2012/035216A1
Compounds of formula (I): in which R1 is a hydrogen atom, or a heterocyclic, cyano, alkoxycarbonyl, alkylsulphonylaminoalkyl or N-hydroxy┬şcarboximidamide group; use thereof as AMPA receptor modulators.  
WO/2012/024083A9
Novel derivatives of dihydro-l,4,2-oxathiazine and dihydro-l,4-dithiine oxides, more particularly, novel derivatives of dihydro-l,4,2-oxathiazine and dmydro-l,4-dithiine oxides that target cysteine residues of biomolecules of pharmacolog...  

Matches 1 - 50 out of 497